Cerebral Creatine Deficiency Syndromes
Autor(a) principal: | |
---|---|
Data de Publicação: | 2013 |
Outros Autores: | , , , |
Tipo de documento: | Artigo |
Idioma: | por |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/1355 |
Resumo: | Introduction: Creatine deficiency syndromes are a recently described group of diseases characterized by inborn errors of creatinemetabolism. Clinical features include a spectrum of neurodevelopment disorders of diverse severity. They are characterized by lowlevels of cerebral creatine caused by different pathogenic mutations concerning the genes coding for creatine synthesis enzymes[arginine: glicyne amidinotransferase (AGAT, EC 2.1.4.1) and guanidinoacetate methyltansferase (GAMT, EC 2.1.1.2)], AGAT andGAMT, respectively, or its transporter (CT1 deficiency), SLC6A8. Enzymatic deficiencies are transmitted as autosomal recessive traits,whereas the transporter deficit is X-linked.Objectives: To characterize the clinical and laboratorial presentation, diagnosis and treatment of cerebral creatine deficiency patients,followed in Hospital Pediátrico Carmona da Mota. The awareness of these inborn errors of metabolism as neurological disorders,namely of neurodevelopment, among the medical community is a secondary aim of the present work.Methods and Material: Retrospective analysis of the clinical files of patients followed in our Hospital and diagnosed with cerebralcreatine deficiency syndrome.Results: Twelve patients belonging to seven different families were diagnosed with creatine deficiency syndromes. Five presentedGAMT deficiency and seven CT1 deficiency. Present ages are 2 to 38 years old. The most common clinical presentations were: globaldevelopment delay in seven patients (two with epilepsy), and speech delay in two patients. Only one patient had communication andsocial interaction dysfunction. In all, global development delay in the range of intellectual delay was identified. The pathognomonic patternof cerebral creatine deficiency in the brain image was demonstrated in eight patients. Pathogenic mutations in GAMT or SLC6A8genes were identified in all cases.Conclusions: The suspicion of cerebral creatine depletion must be considered in all children presenting unexplained global psychomotordevelopment delay. Pre-symptomatic therapy has shown promising results, especially in GAMT deficiency patients. The high rate ofasymptomatic carriers of GAMT mutations in our population makes this disorder eligible to neonatal screening in Portugal. |
id |
RCAP_5cbffc111fcec6c24c2d9de7c810894f |
---|---|
oai_identifier_str |
oai:ojs.www.actamedicaportuguesa.com:article/1355 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
Cerebral Creatine Deficiency SyndromesSíndromes de Deficiência Cerebral de CreatinaIntroduction: Creatine deficiency syndromes are a recently described group of diseases characterized by inborn errors of creatinemetabolism. Clinical features include a spectrum of neurodevelopment disorders of diverse severity. They are characterized by lowlevels of cerebral creatine caused by different pathogenic mutations concerning the genes coding for creatine synthesis enzymes[arginine: glicyne amidinotransferase (AGAT, EC 2.1.4.1) and guanidinoacetate methyltansferase (GAMT, EC 2.1.1.2)], AGAT andGAMT, respectively, or its transporter (CT1 deficiency), SLC6A8. Enzymatic deficiencies are transmitted as autosomal recessive traits,whereas the transporter deficit is X-linked.Objectives: To characterize the clinical and laboratorial presentation, diagnosis and treatment of cerebral creatine deficiency patients,followed in Hospital Pediátrico Carmona da Mota. The awareness of these inborn errors of metabolism as neurological disorders,namely of neurodevelopment, among the medical community is a secondary aim of the present work.Methods and Material: Retrospective analysis of the clinical files of patients followed in our Hospital and diagnosed with cerebralcreatine deficiency syndrome.Results: Twelve patients belonging to seven different families were diagnosed with creatine deficiency syndromes. Five presentedGAMT deficiency and seven CT1 deficiency. Present ages are 2 to 38 years old. The most common clinical presentations were: globaldevelopment delay in seven patients (two with epilepsy), and speech delay in two patients. Only one patient had communication andsocial interaction dysfunction. In all, global development delay in the range of intellectual delay was identified. The pathognomonic patternof cerebral creatine deficiency in the brain image was demonstrated in eight patients. Pathogenic mutations in GAMT or SLC6A8genes were identified in all cases.Conclusions: The suspicion of cerebral creatine depletion must be considered in all children presenting unexplained global psychomotordevelopment delay. Pre-symptomatic therapy has shown promising results, especially in GAMT deficiency patients. The high rate ofasymptomatic carriers of GAMT mutations in our population makes this disorder eligible to neonatal screening in Portugal.Introdução: As síndromes de deficiência cerebral de creatina (OMIM 300036) são um grupo de patologias recentemente descritas,caracterizadas por defeitos congénitos no metabolismo da creatina. A apresentação clínica compreende um espectro variado deperturbações do neurodesenvolvimento. Os baixos níveis de creatina cerebral verificados nestes doentes devem-se a diferentesmutações nos genes que codificam as enzimas de síntese da creatina [arginina:glicina amidinotransferase (AGAT, EC 2.1.4.1), emetiltransferase do ácido guanidinoacético (GAMT, EC 2.1.1.2)], AGAT e GAMT, respectivamente, ambas de transmissão autossómicarecessiva, ou o seu transportador (CT1), SLC6A8, de transmissão ligada ao cromossoma X.Objectivo: Caracterizar o espectro de apresentação clínica e laboratorial dos doentes com o diagnóstico da síndrome de deficiênciade creatina cerebral seguidos no Hospital Pediátrico Carmona da Mota, bem como a sua orientação diagnóstica e terapêutica. Adivulgação destes erros inatos do metabolismo enquanto doenças neurológicas, nomeadamente do neurodesenvolvimento, entre acomunidade médica é outro dos propósitos almejados.Material e Métodos: Análise retrospectiva dos processos clínicos de doentes com o diagnóstico de deficiência cerebral da creatinaseguidos no Hospital Pediátrico.Resultados: Foram identificados doze doentes com défice cerebral da creatina pertencentes a sete famílias. Cinco apresentam deficiênciade metiltransferase do ácido guanidinoacético e sete do transportador de creatina. Têm actualmente entre dois e 38 anos.Os principais motivos de consulta foram: atraso global de desenvolvimento em sete doentes, dois dos quais também apresentavamepilepsia, e atraso da linguagem em outros dois. Apenas num caso o motivo de consulta foi défice de interacção social e de comunicação.Em todos os casos se registou um quociente de desenvolvimento global na faixa da deficiência intelectual. O estudo imagiológicodemonstrou o padrão patognomónico destas síndromes em oito doentes. No estudo genético foram identificadas mutações nos genesGAMT ou SLC6A8 nos doze casos.Conclusões: A suspeita de deficiência de creatina cerebral deve ser considerada em todos os casos de atraso de desenvolvimentopsicomotor sem outra causa evidente. A terapêutica pré-sintomática tem mostrado resultados promissores em algumas crianças comdéfice cerebral de creatina, sobretudo nos défices de GAMT. A elevada taxa de portadores de mutações do gene GAMT em Portugaltorna esta anomalia elegível para o rastreio neonatal no nosso País.Ordem dos Médicos2013-01-28info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttps://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/1355oai:ojs.www.actamedicaportuguesa.com:article/1355Acta Médica Portuguesa; Vol. 25 No. 6 (2012): November-December; 389-398Acta Médica Portuguesa; Vol. 25 N.º 6 (2012): Novembro-Dezembro; 389-3981646-07580870-399Xreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAPporhttps://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/1355https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/1355/948Malheiro, RuiDiogo, LuísaGarcia, PaulaFineza, IsabelOliveira, Guiomarinfo:eu-repo/semantics/openAccess2022-12-20T10:57:46Zoai:ojs.www.actamedicaportuguesa.com:article/1355Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T16:17:05.191503Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
Cerebral Creatine Deficiency Syndromes Síndromes de Deficiência Cerebral de Creatina |
title |
Cerebral Creatine Deficiency Syndromes |
spellingShingle |
Cerebral Creatine Deficiency Syndromes Malheiro, Rui |
title_short |
Cerebral Creatine Deficiency Syndromes |
title_full |
Cerebral Creatine Deficiency Syndromes |
title_fullStr |
Cerebral Creatine Deficiency Syndromes |
title_full_unstemmed |
Cerebral Creatine Deficiency Syndromes |
title_sort |
Cerebral Creatine Deficiency Syndromes |
author |
Malheiro, Rui |
author_facet |
Malheiro, Rui Diogo, Luísa Garcia, Paula Fineza, Isabel Oliveira, Guiomar |
author_role |
author |
author2 |
Diogo, Luísa Garcia, Paula Fineza, Isabel Oliveira, Guiomar |
author2_role |
author author author author |
dc.contributor.author.fl_str_mv |
Malheiro, Rui Diogo, Luísa Garcia, Paula Fineza, Isabel Oliveira, Guiomar |
description |
Introduction: Creatine deficiency syndromes are a recently described group of diseases characterized by inborn errors of creatinemetabolism. Clinical features include a spectrum of neurodevelopment disorders of diverse severity. They are characterized by lowlevels of cerebral creatine caused by different pathogenic mutations concerning the genes coding for creatine synthesis enzymes[arginine: glicyne amidinotransferase (AGAT, EC 2.1.4.1) and guanidinoacetate methyltansferase (GAMT, EC 2.1.1.2)], AGAT andGAMT, respectively, or its transporter (CT1 deficiency), SLC6A8. Enzymatic deficiencies are transmitted as autosomal recessive traits,whereas the transporter deficit is X-linked.Objectives: To characterize the clinical and laboratorial presentation, diagnosis and treatment of cerebral creatine deficiency patients,followed in Hospital Pediátrico Carmona da Mota. The awareness of these inborn errors of metabolism as neurological disorders,namely of neurodevelopment, among the medical community is a secondary aim of the present work.Methods and Material: Retrospective analysis of the clinical files of patients followed in our Hospital and diagnosed with cerebralcreatine deficiency syndrome.Results: Twelve patients belonging to seven different families were diagnosed with creatine deficiency syndromes. Five presentedGAMT deficiency and seven CT1 deficiency. Present ages are 2 to 38 years old. The most common clinical presentations were: globaldevelopment delay in seven patients (two with epilepsy), and speech delay in two patients. Only one patient had communication andsocial interaction dysfunction. In all, global development delay in the range of intellectual delay was identified. The pathognomonic patternof cerebral creatine deficiency in the brain image was demonstrated in eight patients. Pathogenic mutations in GAMT or SLC6A8genes were identified in all cases.Conclusions: The suspicion of cerebral creatine depletion must be considered in all children presenting unexplained global psychomotordevelopment delay. Pre-symptomatic therapy has shown promising results, especially in GAMT deficiency patients. The high rate ofasymptomatic carriers of GAMT mutations in our population makes this disorder eligible to neonatal screening in Portugal. |
publishDate |
2013 |
dc.date.none.fl_str_mv |
2013-01-28 |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/1355 oai:ojs.www.actamedicaportuguesa.com:article/1355 |
url |
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/1355 |
identifier_str_mv |
oai:ojs.www.actamedicaportuguesa.com:article/1355 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.relation.none.fl_str_mv |
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/1355 https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/1355/948 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Ordem dos Médicos |
publisher.none.fl_str_mv |
Ordem dos Médicos |
dc.source.none.fl_str_mv |
Acta Médica Portuguesa; Vol. 25 No. 6 (2012): November-December; 389-398 Acta Médica Portuguesa; Vol. 25 N.º 6 (2012): Novembro-Dezembro; 389-398 1646-0758 0870-399X reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1799130624525598720 |